ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Type 2 Inflammation Targeting Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-33T16543
Home | Market Reports | Health| Health Conditions| Allergies
Global Type 2 Inflammation Targeting Drugs Market Research Report 2024
BUY CHAPTERS

Global Type 2 Inflammation Targeting Drugs Market Research Report 2025

Code: QYRE-Auto-33T16543
Report
September 2025
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Novartis
GSK
Amgen Inc
Astrazeneca plc
Pfizer Inc
TEVA
Otsuka Pharmaceutical
Roche
AbbVie
LEO Pharma
Eli Lilly and Company
Mabpharm
Incyte

Type 2 Inflammation Targeting Drugs Market Size

The global market for Type 2 Inflammation Targeting Drugs was valued at US$ 37149 million in the year 2024 and is projected to reach a revised size of US$ 107564 million by 2031, growing at a CAGR of 16.1% during the forecast period.

Type 2 Inflammation Targeting Drugs Market

Type 2 Inflammation Targeting Drugs Market

Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population. Abnormalities in type 2 immune pathways are important factors in inducing allergic diseases. Type 2 immune pathway refers to an inflammatory pathway in which Th2 cells (T helper 2) play a key role, and various cytokines such as IL-4, IL-5, IL-13, and TSLP are involved. Depending on where the inflammatory reaction occurs, abnormal type 2 immune pathways can induce different allergic diseases, such as skin (atopic dermatitis, chronic spontaneous urticaria, etc.), respiratory tract (chronic sinusitis, asthma, chronic obstruction, etc.) lung disease, etc.), digestive tract (eosinophilic esophagitis), cardiovascular (eosinophilic granulomatous vasculitis), etc. Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; Small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which exert immunomodulatory effects by blocking the JAK/STAT pathway. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.
The Type 2 Inflammation Targeting Drugs market is emerging as a significant area of interest within the pharmaceutical industry, driven by advancements in immunology and a growing understanding of the underlying mechanisms of chronic inflammatory diseases. This class of therapeutics offers targeted approaches to treating conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis by modulating specific pathways involved in Type 2 immune responses. As research continues to uncover the complex roles of cytokines and immune cells in these disorders, the demand for more precise and effective treatment options is expected to rise. The market is also being shaped by increasing investment in biologics and the development of novel monoclonal antibodies, which are poised to transform standard care protocols. Overall, the market outlook appears strong, with opportunities for innovation and expansion across multiple therapeutic areas.
This report aims to provide a comprehensive presentation of the global market for Type 2 Inflammation Targeting Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type 2 Inflammation Targeting Drugs.
The Type 2 Inflammation Targeting Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Type 2 Inflammation Targeting Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Type 2 Inflammation Targeting Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Type 2 Inflammation Targeting Drugs Market Report

Report Metric Details
Report Name Type 2 Inflammation Targeting Drugs Market
Accounted market size in year US$ 37149 million
Forecasted market size in 2031 US$ 107564 million
CAGR 16.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • IL-4R
  • TSLP
  • IL-5
  • JAK
  • IgE
  • IL-13
  • IL-33
  • Others
Segment by Application
  • Atopic Dermatitis
  • Asthma
  • Chronic Sinusitis with Nasal Polyps
  • Chronic Obstructive Pulmonary Disease
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sanofi, AbbVie, Novartis, Incyte, Roche, AstraZeneca, GSK, Eli Lilly and Company, Amgen, Pfizer, Leo Pharma, Teva, Otsuka Pharmaceutical, Mabpharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Type 2 Inflammation Targeting Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Type 2 Inflammation Targeting Drugs Market growing?

Ans: The Type 2 Inflammation Targeting Drugs Market witnessing a CAGR of 16.1% during the forecast period 2025-2031.

What is the Type 2 Inflammation Targeting Drugs Market size in 2031?

Ans: The Type 2 Inflammation Targeting Drugs Market size in 2031 will be US$ 107564 million.

Who are the main players in the Type 2 Inflammation Targeting Drugs Market report?

Ans: The main players in the Type 2 Inflammation Targeting Drugs Market are Sanofi, AbbVie, Novartis, Incyte, Roche, AstraZeneca, GSK, Eli Lilly and Company, Amgen, Pfizer, Leo Pharma, Teva, Otsuka Pharmaceutical, Mabpharm

What are the Application segmentation covered in the Type 2 Inflammation Targeting Drugs Market report?

Ans: The Applications covered in the Type 2 Inflammation Targeting Drugs Market report are Atopic Dermatitis, Asthma, Chronic Sinusitis with Nasal Polyps, Chronic Obstructive Pulmonary Disease, Others

What are the Type segmentation covered in the Type 2 Inflammation Targeting Drugs Market report?

Ans: The Types covered in the Type 2 Inflammation Targeting Drugs Market report are IL-4R, TSLP, IL-5, JAK, IgE, IL-13, IL-33, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 IL-4R
1.2.3 TSLP
1.2.4 IL-5
1.2.5 JAK
1.2.6 IgE
1.2.7 IL-13
1.2.8 IL-33
1.2.9 Others
1.3 Market by Application
1.3.1 Global Type 2 Inflammation Targeting Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Atopic Dermatitis
1.3.3 Asthma
1.3.4 Chronic Sinusitis with Nasal Polyps
1.3.5 Chronic Obstructive Pulmonary Disease
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Type 2 Inflammation Targeting Drugs Market Perspective (2020-2031)
2.2 Global Type 2 Inflammation Targeting Drugs Growth Trends by Region
2.2.1 Global Type 2 Inflammation Targeting Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Type 2 Inflammation Targeting Drugs Historic Market Size by Region (2020-2025)
2.2.3 Type 2 Inflammation Targeting Drugs Forecasted Market Size by Region (2026-2031)
2.3 Type 2 Inflammation Targeting Drugs Market Dynamics
2.3.1 Type 2 Inflammation Targeting Drugs Industry Trends
2.3.2 Type 2 Inflammation Targeting Drugs Market Drivers
2.3.3 Type 2 Inflammation Targeting Drugs Market Challenges
2.3.4 Type 2 Inflammation Targeting Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Type 2 Inflammation Targeting Drugs Players by Revenue
3.1.1 Global Top Type 2 Inflammation Targeting Drugs Players by Revenue (2020-2025)
3.1.2 Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Top Type 2 Inflammation Targeting Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Type 2 Inflammation Targeting Drugs Revenue
3.4 Global Type 2 Inflammation Targeting Drugs Market Concentration Ratio
3.4.1 Global Type 2 Inflammation Targeting Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Type 2 Inflammation Targeting Drugs Revenue in 2024
3.5 Global Key Players of Type 2 Inflammation Targeting Drugs Head office and Area Served
3.6 Global Key Players of Type 2 Inflammation Targeting Drugs, Product and Application
3.7 Global Key Players of Type 2 Inflammation Targeting Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Type 2 Inflammation Targeting Drugs Breakdown Data by Type
4.1 Global Type 2 Inflammation Targeting Drugs Historic Market Size by Type (2020-2025)
4.2 Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Type (2026-2031)
5 Type 2 Inflammation Targeting Drugs Breakdown Data by Application
5.1 Global Type 2 Inflammation Targeting Drugs Historic Market Size by Application (2020-2025)
5.2 Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Type 2 Inflammation Targeting Drugs Market Size (2020-2031)
6.2 North America Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025)
6.4 North America Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Type 2 Inflammation Targeting Drugs Market Size (2020-2031)
7.2 Europe Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025)
7.4 Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size (2020-2031)
8.2 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Type 2 Inflammation Targeting Drugs Market Size (2020-2031)
9.2 Latin America Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025)
9.4 Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size (2020-2031)
10.2 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Type 2 Inflammation Targeting Drugs Introduction
11.1.4 Sanofi Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.1.5 Sanofi Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Type 2 Inflammation Targeting Drugs Introduction
11.2.4 AbbVie Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.2.5 AbbVie Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Type 2 Inflammation Targeting Drugs Introduction
11.3.4 Novartis Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Incyte
11.4.1 Incyte Company Details
11.4.2 Incyte Business Overview
11.4.3 Incyte Type 2 Inflammation Targeting Drugs Introduction
11.4.4 Incyte Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.4.5 Incyte Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Type 2 Inflammation Targeting Drugs Introduction
11.5.4 Roche Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.5.5 Roche Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Type 2 Inflammation Targeting Drugs Introduction
11.6.4 AstraZeneca Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 GSK
11.7.1 GSK Company Details
11.7.2 GSK Business Overview
11.7.3 GSK Type 2 Inflammation Targeting Drugs Introduction
11.7.4 GSK Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.7.5 GSK Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Type 2 Inflammation Targeting Drugs Introduction
11.8.4 Eli Lilly and Company Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.8.5 Eli Lilly and Company Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Type 2 Inflammation Targeting Drugs Introduction
11.9.4 Amgen Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.9.5 Amgen Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Type 2 Inflammation Targeting Drugs Introduction
11.10.4 Pfizer Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.10.5 Pfizer Recent Development
11.11 Leo Pharma
11.11.1 Leo Pharma Company Details
11.11.2 Leo Pharma Business Overview
11.11.3 Leo Pharma Type 2 Inflammation Targeting Drugs Introduction
11.11.4 Leo Pharma Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.11.5 Leo Pharma Recent Development
11.12 Teva
11.12.1 Teva Company Details
11.12.2 Teva Business Overview
11.12.3 Teva Type 2 Inflammation Targeting Drugs Introduction
11.12.4 Teva Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.12.5 Teva Recent Development
11.13 Otsuka Pharmaceutical
11.13.1 Otsuka Pharmaceutical Company Details
11.13.2 Otsuka Pharmaceutical Business Overview
11.13.3 Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Introduction
11.13.4 Otsuka Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.13.5 Otsuka Pharmaceutical Recent Development
11.14 Mabpharm
11.14.1 Mabpharm Company Details
11.14.2 Mabpharm Business Overview
11.14.3 Mabpharm Type 2 Inflammation Targeting Drugs Introduction
11.14.4 Mabpharm Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025)
11.14.5 Mabpharm Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Sanofi
Novartis
GSK
Amgen Inc
Astrazeneca plc
Pfizer Inc
TEVA
Otsuka Pharmaceutical
Roche
AbbVie
LEO Pharma
Eli Lilly and Company
Mabpharm
Incyte
List of Tables
 Table 1. Global Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of IL-4R
 Table 3. Key Players of TSLP
 Table 4. Key Players of IL-5
 Table 5. Key Players of JAK
 Table 6. Key Players of IgE
 Table 7. Key Players of IL-13
 Table 8. Key Players of IL-33
 Table 9. Global Type 2 Inflammation Targeting Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Type 2 Inflammation Targeting Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 11. Global Type 2 Inflammation Targeting Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 12. Global Type 2 Inflammation Targeting Drugs Market Share by Region (2020-2025)
 Table 13. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 14. Global Type 2 Inflammation Targeting Drugs Market Share by Region (2026-2031)
 Table 15. Type 2 Inflammation Targeting Drugs Market Trends
 Table 16. Type 2 Inflammation Targeting Drugs Market Drivers
 Table 17. Type 2 Inflammation Targeting Drugs Market Challenges
 Table 18. Type 2 Inflammation Targeting Drugs Market Restraints
 Table 19. Global Type 2 Inflammation Targeting Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 20. Global Type 2 Inflammation Targeting Drugs Market Share by Players (2020-2025)
 Table 21. Global Top Type 2 Inflammation Targeting Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Type 2 Inflammation Targeting Drugs as of 2024)
 Table 22. Ranking of Global Top Type 2 Inflammation Targeting Drugs Companies by Revenue (US$ Million) in 2024
 Table 23. Global 5 Largest Players Market Share by Type 2 Inflammation Targeting Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 24. Global Key Players of Type 2 Inflammation Targeting Drugs, Headquarters and Area Served
 Table 25. Global Key Players of Type 2 Inflammation Targeting Drugs, Product and Application
 Table 26. Global Key Players of Type 2 Inflammation Targeting Drugs, Date of Enter into This Industry
 Table 27. Mergers & Acquisitions, Expansion Plans
 Table 28. Global Type 2 Inflammation Targeting Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 29. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Type (2020-2025)
 Table 30. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 31. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Type (2026-2031)
 Table 32. Global Type 2 Inflammation Targeting Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 33. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Application (2020-2025)
 Table 34. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 35. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Application (2026-2031)
 Table 36. North America Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. North America Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 38. North America Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Europe Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 41. Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 42. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 44. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 45. Latin America Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 49. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 50. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 51. Sanofi Company Details
 Table 52. Sanofi Business Overview
 Table 53. Sanofi Type 2 Inflammation Targeting Drugs Product
 Table 54. Sanofi Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 55. Sanofi Recent Development
 Table 56. AbbVie Company Details
 Table 57. AbbVie Business Overview
 Table 58. AbbVie Type 2 Inflammation Targeting Drugs Product
 Table 59. AbbVie Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 60. AbbVie Recent Development
 Table 61. Novartis Company Details
 Table 62. Novartis Business Overview
 Table 63. Novartis Type 2 Inflammation Targeting Drugs Product
 Table 64. Novartis Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 65. Novartis Recent Development
 Table 66. Incyte Company Details
 Table 67. Incyte Business Overview
 Table 68. Incyte Type 2 Inflammation Targeting Drugs Product
 Table 69. Incyte Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 70. Incyte Recent Development
 Table 71. Roche Company Details
 Table 72. Roche Business Overview
 Table 73. Roche Type 2 Inflammation Targeting Drugs Product
 Table 74. Roche Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 75. Roche Recent Development
 Table 76. AstraZeneca Company Details
 Table 77. AstraZeneca Business Overview
 Table 78. AstraZeneca Type 2 Inflammation Targeting Drugs Product
 Table 79. AstraZeneca Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 80. AstraZeneca Recent Development
 Table 81. GSK Company Details
 Table 82. GSK Business Overview
 Table 83. GSK Type 2 Inflammation Targeting Drugs Product
 Table 84. GSK Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 85. GSK Recent Development
 Table 86. Eli Lilly and Company Company Details
 Table 87. Eli Lilly and Company Business Overview
 Table 88. Eli Lilly and Company Type 2 Inflammation Targeting Drugs Product
 Table 89. Eli Lilly and Company Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 90. Eli Lilly and Company Recent Development
 Table 91. Amgen Company Details
 Table 92. Amgen Business Overview
 Table 93. Amgen Type 2 Inflammation Targeting Drugs Product
 Table 94. Amgen Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 95. Amgen Recent Development
 Table 96. Pfizer Company Details
 Table 97. Pfizer Business Overview
 Table 98. Pfizer Type 2 Inflammation Targeting Drugs Product
 Table 99. Pfizer Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 100. Pfizer Recent Development
 Table 101. Leo Pharma Company Details
 Table 102. Leo Pharma Business Overview
 Table 103. Leo Pharma Type 2 Inflammation Targeting Drugs Product
 Table 104. Leo Pharma Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 105. Leo Pharma Recent Development
 Table 106. Teva Company Details
 Table 107. Teva Business Overview
 Table 108. Teva Type 2 Inflammation Targeting Drugs Product
 Table 109. Teva Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 110. Teva Recent Development
 Table 111. Otsuka Pharmaceutical Company Details
 Table 112. Otsuka Pharmaceutical Business Overview
 Table 113. Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Product
 Table 114. Otsuka Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 115. Otsuka Pharmaceutical Recent Development
 Table 116. Mabpharm Company Details
 Table 117. Mabpharm Business Overview
 Table 118. Mabpharm Type 2 Inflammation Targeting Drugs Product
 Table 119. Mabpharm Revenue in Type 2 Inflammation Targeting Drugs Business (2020-2025) & (US$ Million)
 Table 120. Mabpharm Recent Development
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources
 Table 124. Authors List of This Report


List of Figures
 Figure 1. Type 2 Inflammation Targeting Drugs Picture
 Figure 2. Global Type 2 Inflammation Targeting Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Type 2 Inflammation Targeting Drugs Market Share by Type: 2024 VS 2031
 Figure 4. IL-4R Features
 Figure 5. TSLP Features
 Figure 6. IL-5 Features
 Figure 7. JAK Features
 Figure 8. IgE Features
 Figure 9. IL-13 Features
 Figure 10. IL-33 Features
 Figure 11. Others Features
 Figure 12. Global Type 2 Inflammation Targeting Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 13. Global Type 2 Inflammation Targeting Drugs Market Share by Application: 2024 VS 2031
 Figure 14. Atopic Dermatitis Case Studies
 Figure 15. Asthma Case Studies
 Figure 16. Chronic Sinusitis with Nasal Polyps Case Studies
 Figure 17. Chronic Obstructive Pulmonary Disease Case Studies
 Figure 18. Others Case Studies
 Figure 19. Type 2 Inflammation Targeting Drugs Report Years Considered
 Figure 20. Global Type 2 Inflammation Targeting Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 21. Global Type 2 Inflammation Targeting Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 22. Global Type 2 Inflammation Targeting Drugs Market Share by Region: 2024 VS 2031
 Figure 23. Global Type 2 Inflammation Targeting Drugs Market Share by Players in 2024
 Figure 24. Global Type 2 Inflammation Targeting Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 25. The Top 10 and 5 Players Market Share by Type 2 Inflammation Targeting Drugs Revenue in 2024
 Figure 26. North America Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. North America Type 2 Inflammation Targeting Drugs Market Share by Country (2020-2031)
 Figure 28. United States Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Canada Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Europe Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Europe Type 2 Inflammation Targeting Drugs Market Share by Country (2020-2031)
 Figure 32. Germany Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. France Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. U.K. Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Italy Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Russia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Ireland Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Share by Region (2020-2031)
 Figure 40. China Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Japan Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. South Korea Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Southeast Asia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. India Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Australia & New Zealand Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Latin America Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Latin America Type 2 Inflammation Targeting Drugs Market Share by Country (2020-2031)
 Figure 48. Mexico Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Brazil Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Share by Country (2020-2031)
 Figure 52. Israel Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. UAE Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 55. Sanofi Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 56. AbbVie Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 57. Novartis Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 58. Incyte Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 59. Roche Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 60. AstraZeneca Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 61. GSK Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 62. Eli Lilly and Company Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 63. Amgen Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 64. Pfizer Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 65. Leo Pharma Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 66. Teva Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 67. Otsuka Pharmaceutical Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 68. Mabpharm Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2020-2025)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Targeted Drugs for Allergic Diseases Market Research Report 2025
Global Anaphylaxis Treatment Market Research Report 2024
Global Peanut Allergy Therapeutics Market Research Report 2024
Global Food Allergy Immunotherapies Market Research Report 2024
Peanut Allergy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Food Allergy Testing Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Allergy Medicine Market Research Report 2024
Global Anti allergic Drugs Market Research Report 2025
Allergy Diagnostics And Treatment Market
Anaphylaxis Autoinjectors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Allergy Diagnostics Reagent Market Research Report 2025
Global Immune System Allergy Treatment Market Research Report 2025
Global Allergy Diagnostics Reagent and Kit Market Research Report 2025
Global Epinephrine Autoinjector Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global Allergy Diagnostic Products Market Research Report 2025
Global Allergic Asthma Therapeutics Market Research Report 2025
Anaphylaxis Epinephrine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Urticaria Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Anaphylaxis Treatment Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Generic Allergy Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Milk Allergy Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-12L17297
Wed Nov 05 00:00:00 UTC 2025

Add to Cart

Global Allergy Apps Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-26A17172
Thu Oct 23 00:00:00 UTC 2025

Add to Cart

Global Specific IgE Blood Based Allergy Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-33D17671
Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Allergen Specific IgE Tests Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-34W17496
Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions